RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2016; 116(04): 590-591
DOI: 10.1160/TH16-08-0602
DOI: 10.1160/TH16-08-0602
Invited Editorial Focus
Direct oral anticoagulants (DOACs) and pregnancy: A plea for better information
Autoren
Weitere Informationen
Publikationsverlauf
Received:
03. August 2016
Accepted:
03. August 2016
Publikationsdatum:
20. November 2017 (online)
-
References
- 1 Hall JG, Pauli RM, Wilson KM.. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980; 68: 122-140.
- 2 Wainwright H, Beighton P.. Warfarin embryopathy: fetal manifestations. Virchows Arch 2010; 457: 735-739.
- 3 Ginsberg JS, Hirsh J, Turner DC. et al. Risks to the fetus of anticoagulant therapy during pregnancy. [Review]. Thromb Haemost 1989; 61: 197-203.
- 4 Weitz JI.. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-698.
- 5 Agency EM.. CHMP Assessment report for Xarelto [PDF]. London: European Medicines Agency; 2016. [Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000944/WC500057122.pdf
- 6 Beyer-Westendorf J, Michalski F, Tittl L. et al Pregnancy outcome in patients exposed to direct oral anticoagulants – and the challenge of event reporting. Thromb Haemost 2016; 116: 651-658.